Scratch that link....basically the last few paragraphs were as follows:
Cautious Appraisal of the Growth-Hormone Analog in HIV-Positive Patients
"This drug has not been approved by the FDA yet," said Jens Lundgren, MD, from the University of Copenhagen HIV Programme in Denmark.
"It may be that tesamorelin adversely affects other metabolic parameters, which is a concern. Are the cosmetic effects worth the side effects? The FDA will decide that," he noted.
In Dr. Lundgren's opinion, even if tesamorelin is approved, it will not be used that often. "As soon as the drug is stopped, the fat comes back, so treatment would have to be lifelong," he explained. Patients with VAT could try diet and exercise for their bellies, he added.
Tesamorelin might find a role as a treatment for the few patients with pathologic interabdominal fat that interferes with respiration, Dr. Lundgren continued. "If there is a niche for this drug, this might be it," he stated.
In addition, this was stated in the middle of the article....
Tesamorelin is an investigative analog of growth-hormone-releasing factor and growth-hormone-releasing hormone. The drug is pending approval by the US Food and Drug Administration (FDA), but some investigators are not enthusiastic about using it, except perhaps for specific indications.
These results suggest that tesamorelin significantly reduces VAT in different sub-populations of HIV-infected patients with abdominal lipohypertrophy, including women, patients with hepatitis, patients with detectable viral load, and non-caucasian patients. Long term safety was similar between these subgroups and the main population of treated patients.